LiliumX Information

LiliumX is a spinout of the University of Oxford, focused on the development of next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating bi-/multispecificity, multivalency and drug-conjugation into a single discovery process via our Universal Assembly Platform™. Our internal research focus is on solid tumours poorly addressed by immunotherapy, in addition to select platform collaborations.